In brief, our research confirmed that RGS exhibited a dramatic and selective anti-tumor effect in KRAS-mutant colorectal cancer when compared with RAS wild-type CRC, and that this anti-tumor effect was associated with RGS-induced inhibition of RAS signaling. The gene discussed is PITX2; the disease is colorectal cancer.